Identification of nanopeptide from HTLV-III, ARV-2 and LAVBRU envelope gp120 determining binding to T4 cell surface protein.
The information contained in the primary structure of HIV envelope gp120 determining its biological activity, was analyzed by the use of the informational spectrum method. The parameter determining the interaction between gp120 and T4 cell-surface protein was defined. On the basis of this data in the conserved region of gp120 from HTLV-III, LAVBRU and ARV-2, a nanopeptide NAKTIIVQL was identified as a potential binding domain which could be used as a component of an effective therapeutic agent or as a vaccine component.
Veljković
V
V
Laboratory for Multidisciplinary Research RA 180/2, Boris Kidric Institute, Beograd, Yugoslavia.
Metlas
R
R
D000595:Amino Acid Sequence; D000954:Antigens, Surface / Q000378:metabolism*; D002462:Cell Membrane; D006678:HIV; D015699:HIV Envelope Protein gp120; D008969:Molecular Sequence Data; D009842:Oligopeptides / Q000235:genetics / Q000378:metabolism*; D015717:Peptide T; D011485:Protein Binding; D015728:Receptors, HIV; D011991:Receptors, Virus / Q000378:metabolism*; D012191:Retroviridae Proteins / Q000235:genetics*; D012689:Sequence Homology, Nucleic Acid; D013329:Structure-Activity Relationship; D014759:Viral Envelope Proteins / Q000235:genetics*
D000954:Antigens, Surface; D015699:HIV Envelope Protein gp120; D009842:Oligopeptides; D015728:Receptors, HIV; D011991:Receptors, Virus; D012191:Retroviridae Proteins; D014759:Viral Envelope Proteins; D015717:Peptide T; C060222:NAKTIIVQL nanopeptide